Skip to content
thestock.space

On 6 Nov 2026, Godavari Drugs was priced at ₹119.70, or 23.6× trailing earnings, against an industry P/E of 28.7×, and the shares are 17% below their 52-week high. Sales fell 13% a year over 3 years while net profit grew 2.6%; its ROCE of 7.4% is the lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 1.01× equity. It is a small-cap company with a market cap of ₹131 Cr, ranked 109th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 39% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹118.30
Day high
₹120.00
Day low
₹117.90
Prev. close
₹119.10
Volume
856

Health check

2 good · 4 to check
  • ReturnsAhead

    +39.4% over a year, better than 5 of 7 peers.

  • Price tagCheaper

    P/E 23.6 vs industry 28.7.

  • GrowthSlow

    Sales −12.8%, profit +2.6% a year over 3 years.

  • ProfitabilityWeak

    ROCE 7.4% vs peer median 17.9%.

  • Balance sheetStretched

    Debt 1.01× equity, interest covered 2.4×, Piotroski 3 of 9.

  • Red flags1 to check

    Return on equity is low at 6.9%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹131 Cr, #109 of 154 in its industry by size.

Defensive

Beta 0.38 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹111 Cr · profit ₹4 Cr
Market cap
₹131 Cr
Small cap
P/E
23.6
Industry 28.7
Price to book
1.19
Peers 4.99
Dividend yield
0.00%
ROE
6.9%
Peers 14.7%
ROCE
7.4%
Peers 17.9%
Debt to equity
1.01
Debt ₹76 Cr
EPS (TTM)
₹5.08
OPM (TTM)
9.0%
Net margin 3.7%
Sales growth
+17.4%
Latest quarter vs a year ago
Profit growth
+6.6%
Latest quarter vs a year ago
Price to sales
1.18
EV/EBITDA 16.8

Strengths and risks

Strengths

  • Quarterly sales up 17.4% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 6.9%.

Derived automatically from reported figures. Not a recommendation.

About Godavari Drugs

Godavari Drugs Limited manufactures and sells active pharmaceutical ingredients (APIs), drug intermediaries, and fine chemicals in India. The company offers APIs, including ciprofloxacin hydrochloride (HCL), ciprofloxacin lactate, ciprofloxacin betaine, carbamazepine, enrofloxacin, mefenamic acid, ambroxol hydrochloride, piracetam, as well as 2,5-dihydroxy-1,4- dithiane. It also provides loan licenses and contract manufacturing services for APIs and drug…

Headquarters
Secunderabad
Employees
112
Sector
Healthcare
ISIN
INE362C01012
Website
godavaridrugs.com

Price range

52 weeks

₹69.70₹144.35

Today

₹117.90₹120.00
Avg volume (3M)
10K
1-year return
plus 39.4%
From 52-week high
minus 17.1%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
GODAVARIGodavari Drugs119.70plus 0.50%13123.61.197.4%6.9%9.0%−12.8%2.6%0.00%plus 39.4%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
23.826.622.233.228
20.924.719.730.225.4
2.922.52.92.5
12.2%7.5%11.2%8.9%9.0%
00.600.10.2
10.91.110.9
0.60.60.60.60.6
––0.30.1–
1.31.111.61.2
20.1%10.8%25.9%20.2%5.8%
110.81.31.1
1.381.331.011.641.10

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
−12.8%
Profit CAGR 3Y
+2.6%
EPS CAGR 3Y
+2.1%
ROE
6.9%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
160157113106
–minus 1.8%minus 27.7%minus 6.7%
15014310194.9
9.713.512.111
6.1%8.6%10.7%10.4%
−0.2−0.7−0.3−0.3
2.93.83.83.5
1.922.42.4
0.2−0.100.4
4.96.95.65.1
23.3%19.8%22.1%19.2%
3.85.54.44.1
–+46.6%minus 21.1%minus 6.6%
5.037.375.825.36

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
7.57.57.510.1
25.931.435.865.7
57.357.864.381.9
30.73835.442.7
121135143200
344562.686.8
9.118.329.956.5
0.10.10.10
00.1012
78.371.250.445
121135143200

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
13.218.411.20.7
−8.6−13.2−19.5−25.9
−3.8−5.78.137.4
0.8−0.5−0.212.1
−9.3−13.2−20−26.7
3.95.2−8.8−26

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders. Institutions hold about 2.2% (Yahoo estimate).

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you